CASP1 and bronchopulmonary dysplasia: For the first time, our animal experiments demonstrated that VX-765 alleviated tissue injury and effectively treated BPD in preclinical models by inhibiting caspase-1, thereby blocking the maturation of proinflammatory cytokines.